| Literature DB >> 35708873 |
Xuan Zhou1,2, Lili Yu1,2, Lijuan Wang1,2, Jiarui Xiao1,2, Jing Sun1,2, Yajing Zhou1,2, Xiaolin Xu1,2, Wanghong Xu3, Athina Spiliopoulou4, Maria Timofeeva5, Xiaomeng Zhang6, Yazhou He7, Haomin Yang8,9, Harry Campbell6, Ben Zhang7, Yimin Zhu1,2, Evropi Theodoratou6, Xue Li10,11.
Abstract
Alcohol intake is thought to be a risk factor for breast cancer, but the causal relationship and carcinogenic mechanisms are not clear. We performed an up-to-date meta-analysis of prospective studies to assess observational association, and then conducted MR analysis to make causal inference based on the genetic predisposition to alcohol consumption ("drinks per week") and pathological drinking behaviours ("alcohol use disorder" and "problematic alcohol use"), as well as genetically predicted DNA methylation at by alcohol-related CpG sites in blood. We found an observational dose-response association between alcohol intake and breast cancer incidence with an additional risk of 4% for per 10 g/day increase in alcohol consumption. Genetic predisposition to alcohol consumption ("drinks per week") was not causally associated with breast cancer incidence at the OR of 1.01 (95% CI 0.84, 1.23), but problematic alcohol use (PAU) was linked to a higher breast cancer risk at the OR of 1.76 (95% CI 1.04, 2.99) when conditioning on alcohol consumption. Epigenetic MR analysis identified four CpG sites, cg03260624 near CDC7 gene, cg10816169 near ZNF318 gene, cg03345232 near RIN3 gene, and cg26312998 near RP11-867G23.13 gene, where genetically predicted epigenetic modifications were associated with an increased breast cancer incidence risk. Our findings re-affirmed that alcohol consumption is of high risk for breast cancer incidence even at a very low dose, and the pathogenic effect of alcohol on breast cancer could be due to pathological drinking behaviour and epigenetic modification at several CpG sites, which could be potential intervention targets for breast cancer prevention.Entities:
Keywords: Alcohol; Breast cancer; DNA methylation; Mendelian randomisation
Mesh:
Substances:
Year: 2022 PMID: 35708873 PMCID: PMC9329409 DOI: 10.1007/s10654-022-00886-1
Source DB: PubMed Journal: Eur J Epidemiol ISSN: 0393-2990 Impact factor: 12.434